English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Andrey N. Sokolov 1, Elena N. Parovichnikova 1, Vera V. Troitskaya 1, Larisa A. Kuzmina 1, Irina V. Galtseva 1, Sergei M. Kulikov 1, Sergey N. Bondarenko 2, Irina A. Lukyanova 1, Tatiana I. Lobanova 1, Ekaterina I. Usikova 1, Ksenia I. Zarubina 1, Olga A. Gavrilina 1, Julia O. Davidova 1, Nikolai M. Kapranov 1, Valeriy G. Savchenko 1 1 National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russia 2 Raisa Gorbacheva Memorial Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia BCR/ABL, IKZF deletions and FLT3-ITD as the targets for relapsed/refractory B-cell acute lymphoblastic leukemia treatment: Blinatumomab combined with Tyrosine kinase inhibitors and ATRA Cellular Th erapy and Transplantation (CTT). Vol. 9, No. 1, 2020 doi: 10.18620/ctt-1866-8836-2020-9-1-38-46 Submitted: 28 February 2020, accepted: 27 March 2020

cellular therapy and transplantation

BCR/ABL, IKZF deletions and FLT3-ITD as the targets for relapsed/refractory B-cell acute lymphoblastic leukemia treatment: Blinatumomab combined with Tyrosine kinase inhibitors and ATRA